A rise in the use of non-FDA-approved diabetes and obesity medications has spurred health care professionals and medical ...

Weight loss injectables like Ozempic have gained popularity in Bengaluru, with patients sourcing them from abroad. The ...

Germany's financial markets watchdog is looking at whether Bayer fairly disclosed plans for shareholder approval of a capital ...

Compounded versions of popular drugs used for weight loss including Wegovy and Zepbound will soon no longer be available ...

We recently compiled a list of the 10 Best Low Risk Stocks To Buy in 2025. In this article, we are going to take a look at ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate ...

The diabetes and weight loss drug market is heating up in 2025, with significant growth signs everywhere. According to a recent study from Research and Markets, industry growth is running at an ...

How weight loss drugs actually work, and how big-name prescriptions differ from each other. What investors need to know about ...

Novo Nordisk's trial results for CagriSema, a next-gen obesity and diabetes drug, showed a 15.7% weight reduction in overweight patients with type 2 diabetes. Despite promising outcomes, shares ...

The weight-loss drug market is evolving at a rapid speed, with leading pharma companies including Novo Nordisk and Eli Lilly ...